Immunotherapeutic strategies for cutaneous squamous cell carcinoma prevention in xeroderma pigmentosum

Br J Dermatol. 2019 Nov;181(5):1095-1097. doi: 10.1111/bjd.18144. Epub 2019 Aug 7.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Carcinoma, Squamous Cell / etiology
  • Carcinoma, Squamous Cell / pathology
  • Carcinoma, Squamous Cell / prevention & control*
  • Female
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use*
  • Ipilimumab / therapeutic use
  • Male
  • Skin Neoplasms / etiology
  • Skin Neoplasms / pathology
  • Skin Neoplasms / prevention & control*
  • Treatment Outcome
  • Xeroderma Pigmentosum / complications
  • Xeroderma Pigmentosum / drug therapy*
  • Young Adult

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • Immune Checkpoint Inhibitors
  • Ipilimumab
  • pembrolizumab